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Introduction
Overactive bladder (OAB) syndrome has been
deﬁned by the International Continence Society as ‘a
syndrome comprising the symptoms of urgency, with
or without urgency incontinence, usually with fre-
quency and nocturia’ (1). Although OAB is not life-
threatening, it signiﬁcantly impairs patients’ quality
of life (2).
Pharmacological management using antimuscarinic
agents remains the mainstay of therapy and effec-
tively reduces OAB symptoms (3). However, despite
the proven efﬁcacy of such agents, their tolerability
may be limited by adverse events (AEs), mostly dry
mouth (4). In fact, these adverse events often lead to
poor compliance and discontinuation of therapy (5).
OAB follows a chronic course requiring long-term
therapy, so new agents with proven efﬁcacy and bet-
ter tolerability are required.
A new-generation antimuscarinic agent, solifenacin
succinate (Vesicare
 ; Astellas Pharma Co. Ltd, Tokyo,
Japan), is a once-daily oral agent that shows apparent
functional selectivity for the bladder over other organs
in animal models (6). In phase 2 trials, symptomatic
OAB patients have shown statistically signiﬁcant
reductions in voiding frequency and a signiﬁcant
increase in volume voided per void with doses of 5, 10
and 20 mg once daily (7). In large phase 3 trials, soli-
fenacin 5 or 10 mg once daily demonstrated good efﬁ-
cacy and tolerability proﬁles, and these improvements
were maintained in a 40-week open-label extension
study of two of the phase 3 trials (8–12).
Until now there have been no published compara-
tive data between solifenacin and tolterodine in
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SUMMARY
Purpose: We assessed the efﬁcacy and safety of solifenacin compared with tolte-
rodine for treatment of overactive bladder (OAB) in Korean patients. Materials
and methods: The study was randomised, double-blind, tolterodine-controlled
trial in Korea. Patients had average frequency of ‡ 8 voids per 24 h and episodes
of urgency or urgency incontinence ‡ 3 during 3-day voiding diary period. Patients
were randomised to 12-week double-blind treatment with either tolterodine imme-
diate release (IR) 2 mg twice daily (TOL4) or solifenacin 5 mg (SOL5) or 10 mg
(SOL10) once daily. The outcome measure was mean change in daily micturition
frequency, volume, daily frequency of urgency incontinence, urgency and nocturia
from baseline to week 12. Quality of life was assessed using the King’s Health
Questionnaire. Results: A total of 357 were randomised and 329 were evaluated
for efﬁcacy. All voiding parameters recorded in micturition diary improved after
treatment in all three groups. Mean changes in volume voided were 19.30 ml
(26.69%) in TOL4, 30.37 ml (25.89%) in SOL5 and 37.12 ml (33.36%) in SOL10
group (p = 0.03). Speed of onset of SOL10 efﬁcacy on urgency incontinence was
faster than that of SOL5 and TOL4. Quality of life improved in all three groups.
Dry mouth was the most common adverse event; its incidence was the lowest in
SOL5 group (7.63%, compared with 19.49% and 18.64% in SOL10 and TOL4
groups respectively). Conclusions: Solifenacin succinate 5 and 10 mg once daily
improve OAB symptoms with acceptable tolerability levels compared with toltero-
dine IR 4 mg. Solifenacin 5 mg is a recommended starting dose in Korean patients
with OAB.
What’s known
• Pharmacological management using
antimuscarinic agents remains the mainstay of
therapy and effectively reduces OAB symptoms.
• A new-generation antimuscarinic agent,
solifenacin succinate is a once-daily oral agent
that shows apparent functional selectivity for
the bladder over other organs in animal models.
• There have been no published comparative data
between solifenacin and tolterodine in Asian
individuals.
What’s new
• Compared with tolterodine, the treatment of
solifenacin induces the improvement in OAB
symptom and quality of life in Korean patients
with OAB.
• This is the ﬁrst report to compare efﬁcacy and
safety of solifenacin succinate with tolterodine
in Asian people with OAB. Solifenacin succinate
5 and 10 mg improve OAB symptoms and
solifenacin 5 mg is a recommended starting
dose.
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efﬁcacy and tolerability of solifenacin 5 and 10 mg
once daily and tolterodine 2 mg twice daily in
patients with symptoms of OAB.
Patients and methods
This multicentre, randomised, double-blind, toltero-
dine-controlled phase 3 trial was conducted at 16
university hospitals in Korea. The procedures of this
study complied with the guidelines provided by the
Declaration of Helsinki and were in accordance with
the International Conference on Harmonization
Good Clinical Practice guidelines. The study protocol
was approved by the institutional review board at
each study site.
The objectives of the study were to assess efﬁcacy
and tolerability of 12-week treatment with solifenacin
5 mg (SOL5) and 10 mg (SOL10) compared with
12-week tolterodine immediate-release 4 mg (TOL4)
in patients with OAB. At the time of study, the tolte-
rodine extended-release (ER) formulation was not
available in Korea. The primary outcome measure
was change in the mean daily micturition frequency
from baseline to end-point. The secondary outcome
measures were changes from baseline in the mean
micturition volume per voiding, mean daily (24 h)
urgency incontinence frequency, mean daily number
of urgency episodes, mean daily number of nocturia
episodes according to the micturition diary and qual-
ity of life as assessed by the King’s Health Question-
naire (13,14). Safety was assessed by AEs, laboratory
tests, vital signs and postvoid residual (PVR) vol-
umes as measured by bladder scans.
Eligible patients visited the investigational sites for
screening (visit 1), at the end of the placebo run-in
period (visit 2) and at weeks 4, 8 and 12 of the dou-
ble-blind period (visits 3, 4 and 5). Men and women
aged ‡ 18 years with symptoms of OAB for
‡ 3 months were eligible for screening and study
enrolment. To be eligible for randomisation after the
2-week placebo run-in period, patients had to have
had an average frequency of ‡ 8 voids per 24 h and
have experienced at least three episodes of urgency
or three episodes of urgency incontinence during the
3-day voiding diary period. Exclusion criteria
included clinically signiﬁcant bladder outlet obstruc-
tion, a PVR volume of > 200 ml, incontinence for
which stress was determined to be the predominant
factor, presence of a neurological cause for detrusor
muscle overactivity, evidence of urinary tract infec-
tion or bladder stones, previous pelvic irradiation, or
previous or current malignant disease in the pelvic
organs, any medical condition contraindicating the
use of antimuscarinic medication (including narrow-
angle glaucoma and urinary or gastric retention),
non-pharmacological treatment for OAB including
electrostimulation therapy or start of a bladder train-
ing programme during the 2 weeks before or during
the study, diabetic neuropathy, use of drugs intended
to treat incontinence, use of any drugs with choliner-
gic or anticholinergic side effects and participation in
a clinical trial within 30 days before study entry.
Women of childbearing potential who were pregnant
or nursing, intending to become pregnant during the
study, or who were not using reliable contraceptive
methods were ineligible.
At an initial screening visit, the patients provided
a medical history and underwent a physical examina-
tion, bladder scan for PVR volume, blood and uri-
nalysis and an electrocardiogram. Eligible patients
received placebo twice daily (morning and evening)
over a 2-week run-in period. During the 3 days
before the next visit, patients recorded episodes of
urgency and urgency incontinence, the times of void-
ing and volumes voided per void in a voiding diary.
After the run-in period, eligible patients were rando-
mised equally to 12-week double-blind treatment
with TOL4, SOL5 or SOL10. To maintain blinding,
all patients continued to take medication twice daily
(using placebo tablets and capsules as necessary) dur-
ing the 12-week treatment period. Patients were
regarded compliant if they had taken at least 70% of
the required study medication.
Adverse events were evaluated for individuals
receiving at least one dose of active study medica-
tion. At each visit, any AE reported in response to
general and non-speciﬁc questioning by the investi-
gator, or self-reported by the patient was recorded
with the severity and likely causality to study medi-
cation. Safety assessments at weeks 4, 8 and 12
included vital signs, physical examinations and AE
recordings. Laboratory screening and electrocardio-
gram scans were repeated at the end of the study.
The PVR volume was assessed by bladder scanning
(the same method was used for each patient) at the
start and ﬁnish of the 12-week treatment period.
Efﬁcacy comparison among treatment groups used
the hierarchical (step-down) test procedure. ANOVA
was used to compare the change from baseline to
end-point in the mean daily micturition frequency
between SOL10 and TOL4 (a non-inferiority test
using 95% conﬁdence interval). If SOL10 was found
not to be inferior to TOL4, the hierarchical (step-
down) test procedure was progressed to the second
step. The second step analysis compared SOL5 and
TOL4. The paired t-test was used to analyse the
mean change from baseline to end-point, and the
Stuart-Maxwell chi-square test, McNemar’s chi-
square test, Mantel-Haenszel chi-square test and
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from the normal range. For subject withdrawal, data
available at the point of withdrawal were analysed.
Missing data were accepted as such. Nonetheless,
data analysis with the last observation carried for-
ward (LOCF) method was performed and presented
for efﬁcacy analysis. With the LOCF analysis, the
missing values are replaced by the last observed value
of that variable. The statistical analyses of the AEs
were done by Fisher’s exact test.
Results
A total of 538 patients with OAB were screened, of
whom 357 were randomised and 354 were treated.
The efﬁcacy analysis included all randomised patients
who had efﬁcacy data available from the baseline and
at least one on-treatment visit (329 patients). In all,
61 patients (17.1%) discontinued the study before
completion; this was because of AEs for 14 patients
(3.9%), withdrawal of consent for 34 patients (9.5%)
and other reasons for 13 patients (3.7%). A total of
81.7% of patients in the SOL5 group, 82.4% in the
SOL10 group and 84.8% in the TOL4 group had
their ﬁnal (end-point) efﬁcacy evaluation at week 12
(Figure 1).
Baseline characteristics and demographics were
similar among all treatment groups as shown in
Table 1. The mean age of all patients was 52.65–
53.07 years. Of all patients, 24.32–30.36% had
received previous drug treatment for OAB and
42.06–52.25% reported urgency incontinence. At
baseline, there were no differences in voiding param-
eters among the three groups (p > 0.05).
Table 2 shows the mean changes in all efﬁcacy vari-
ables from baseline to end-point in the three groups.
After the 12-week treatment, these parameters
improved. The improvement rate was the greatest in
the SOL10 group, followed by the SOL5 and TOL4
groups (Figure 2). A non-inferiority test showed that
the lower limit of the 95% conﬁdence interval was
)0.25, exceeding the limit of non-inferiority of )1. It
showed that SOL10 was not inferior to TOL4, so the
second step analysis was performed to compare SOL5
and TOL4. This showed that the lower limit of the
95% conﬁdence interval was )0.49, exceeding the limit
of non-inferiority of )1. Therefore, we also showed
that SOL5 was non-inferior to TOL4.
n = 538 
n = 357 
n = 120  n = 119  n = 118 
n = 118 treated 
n = 21 
Discontinued 
n = 18 
Discontinued 
n = 118 Treated  n = 118 treated 
n = 22 
Discontinued 
n = 98 
Completed 
n = 15 
Protocol violation 
n = 10 
Protocol violation 
n = 8 
Protocol violation 
n = 92 
PPS(per-protocol set) 
n = 88 
PPS(per-protocol set) 
n = 83 
PPS(per-protocol set) 
n = 98 
Completed 
n = 100 
Completed 
Solifenacin succinate 5 mg
qd
Consent withdrawn : 10 
Adverse event : 5 
Lost follow-up : 3 
Protocol violation : 3 
Consent withdrawn : 13 
Adverse event : 7 
Protocol violation : 1 
Investigator’s discretion : 1 
Consent withdrawn : 11 
Adverse event : 2 
Lost follow-up : 2 
Protocol violation : 1 
Investigator’s discretion : 1 
Others : 1 
Solifenacin succinate 10 mg
qd
Tolterodine 2 mg bid 
Screened 
Randomized 
Figure 1 Patient disposition
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micturition volume per voiding compared with
TOL4 group (p = 0.04). Urgency incontinence epi-
sodes dramatically decreased in SOL10 group at visit
3 (4 week) compared with other groups although
there was no statistical signiﬁcance at end-point.
Subgroup analysis showed that in patients with
dry OAB, the changes in mean daily micturition fre-
quency from baseline were )2.92 in the SOL10 group
and )1.85 in the TOL4 group (p = 0.019). In male
patients with wet OAB, the changes in mean daily
urgency incontinence frequency from baseline were
)2.92 in the SOL10 group and )1.85 in the TOL4
group (p = 0.037).
Quality of life improved in all three groups using
the King’s Health Questionnaire. But both solifenacin
treatments (10 and 5 mg) produced greater improve-
ments from baseline compared with TOL4, although
these results were not statistically signiﬁcant
(Table 3).
The discontinuation rates because of AEs were low
and were similar for the three treatment arms. The
percentages of patients discontinuing treatment
owing to an AE were 4.24% (5⁄118), 5.93% (7⁄118)
and 1.69% (2⁄118) in the SOL5, SOL10 and TOL4
groups, respectively (p = 0.28). The incidences of
AEs (‡ 2%) after medication are listed in Table 4.
Among the treatment groups, the incidence of the
most common AE, dry mouth, was lowest in the
SOL5 group (7.63%, compared with 19.49% and
18.64% in the SOL10 and TOL4 groups, respectively;
p = 0.01). Constipation, which was mainly mild or
Table 1 Patient demographics at baseline
Characteristic
Solifenacin succinate
p-value 5m gq d( N = 107) 10 mg qd (N = 111) Tolterodine 2 mg bid (N = 111)
Age (years)
Mean 53.07 52.65 53.05 0.9568*
SD 10.52 12.71 12.19
Median 52.00 54.00 53.00
Range 25.00–86.00 23.00–80.00 24.00–78.00
Gender
Male 17 (15.39) 28 (25.23) 23 (20.72) 0.2349
Female 90 (84.11) 83 (74.77) 88 (79.28)
Weight (kg)
Mean 59.62 60.18 59.09 0.6722*
SD 9.85 8.92 8.44
Median 59.00 59.00 58.00
Range 42.00–110.00 43.00–85.00 42.00–81.00
Height (cm)
Mean 157.93 159.83 158.64 0.1364*
SD 6.62 7.57 7.12
Median 158.00 159.00 158.00
Range 139.00–173.00 140.00–181.00 141.30–182.00
Pulse (time⁄min)
Mean 74.13 73.55 72.18 0.3342*
SD 10.97 9.96 9.00
Median 74.00 72.00 72.00
Range 48.00–120.00 52.00–109.00 52.00–103.00
Diastolic BP (mmHg)
Mean 123.82 120.70 124.77 0.2053*
SD 17.83 16.96 18.50
Median 122.00 120.00 123.00
Range 70.00–172.00 88.00–177.00 90.00–174.00
Systolic BP (mmHg)
Mean 76.71 74.77 76.28 0.4327*
SD 11.99 10.83 12.18
Median 79.00 74.00 74.00
Range 40.00–108.00 51.00–106.00 50.00–114.00
*ANOVA. Chi-square test. BP, blood pressure.
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14.41%, 2.54% of patients in the SOL5, SOL10 and
TOL4 groups, respectively (p = 0.003). The incidence
of constipation was not statistically different between
SOL5 and TOL4 group (p = 0.215) but different
between SOL10 and TOL4 group (p = 0.002).
Blurred vision (mild in most cases) was reported in
13.56%, 16.95% and 10.17% of patients in the SOL5,
SOL10 and TOL4 groups, respectively (p = 0.335).
There were no clinically relevant changes in vital
signs, physical examination ﬁndings, laboratory val-
ues or electrocardiogram results. PVR volumes
increased in all groups but they were not clinically
signiﬁcant (Table 5). There were no differences of
PVR according to the treatment groups and gender
(p = 0.826, 0.227), although male patients had more
increased PVR than female.
Discussion
Overactive bladder substantially compromises
patients’ quality of life. Therefore, effective treatment
of OAB must result in a meaningful reduction in all
of these symptoms. Currently, available antimuscari-
nic agents effectively relieve symptoms and are com-
parable in having similar efﬁcacies (15). Solifenacin
is a potent M3-selective receptor antagonist with
high functional selectivity for the urinary bladder.
This randomised tolterodine-controlled clinical
trial evaluated the clinical efﬁcacy of different doses
Table 2 The mean changes in efﬁcacy variables with solifenacin and tolterodine from baseline to end-point
Solifenacin succinate
Tolterodine 2 mg bid 5m gq d l 0m gq d
Mean daily micturition frequency
Baseline 11.26 ± 2.78 11.19 ± 2.82 11.44 ± 2.81
Visit 3 9.60 ± 2.46 9.21 ± 2.46 9.88 ± 2.48
Visit 4 9.37 ± 2.87 8.83 ± 2.63 9.76 ± 2.63
Visit 5 9.01 ± 2.70 8.59 ± 2.70 9.23 ± 2.64
End-point 9.08 ± 2.58 8.71 ± 2.73 9.30 ± 2.61
End-point baseline (p = 0.78) )2.18 ()18.29%) )2.47 ()20.95%) )2.14 ()16.90%)
Mean micturition volume per voiding
Baseline 147.22 ± 51.11 154.03 ± 49.77 147.74 ± 49.06
Visit 3 171.09 ± 62.77 189.63 ± 63.24 167.86 ± 53.05
Visit 4 175.44 ± 62.21 194.56 ± 75.21 165.35 ± 58.61
Visit 5 181.11 ± 59.44 196.98 ± 69.96 177.93 ± 68.26
End-point 177.38 ± 59.08 198.99 ± 73.58 177.08 ± 66.41
End-point baseline (p = 0.53) 30.16 (25.89%) 44.97 (33.36%) 29.34 (26.69%)
Mean daily urgency incontinence frequency
Baseline 1.92 ± 2.19 2.58 ± 2.91 1.74 ± 1.55
Visit 3 0.97 ± 1.49 0.76 ± 1.10 0.90 ± 1.16
Visit 4 0.95 ± 1.81 0.77 ± 1.17 1.03 ± 1.41
Visit 5 0.78 ± 1.76 0.72 ± 1.51 0.67 ± 1.16
End-point 0.78 ± 1.74 0.75 ± 1.49 0.72 ± 1.18
End-point baseline (p = 0.14) )1.14 ()59.38%) )1.84 ()57.60%) )1.02 ()52.30%)
Mean daily number of urgency episodes
Baseline 4.29 ± 3.45 3.81 ± 3.04 3.89 ± 3.12
Visit 3 2.32 ± 3.00 2.09 ± 2.49 2.32 ± 2.86
Visit 4 2.11 ± 2.74 1.72 ± 2.40 1.83 ± 2.54
Visit 5 1.77 ± 2.74 1.42 ± 2.21 1.60 ± 2.88
End-point 1.79 ± 2.66 1.47 ± 2.34 1.68 ± 3.02
End-point baseline (p = 0.51) )2.50 ()57.72%) )2.35 ()63.50%) )2.20 ()55.43%)
Mean number of nocturia episodes
Baseline 1.82 ± 1.27 1.73 ± 1.07 1.77 ± 1.00
Visit 3 1.34 ± 1.14 1.28 ± 0.99 1.40 ± 0.96
Visit 4 1.31 ± 1.19 1.11 ± 0.98 1.25 ± 1.02
Visit 5 1.13 ± 1.12 1.07 ± 0.94 1.17 ± 1.09
End-point 1.15 ± 1.11 1.14 ± 1.01 1.23 ± 1.13
End point baseline (p = 0.85) )0.67 ()31.41%) )0.60 ()28.88%) )0.54 ()24.85%)
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least 3 months. In the evaluation of primary efﬁcacy
outcome measure at end-point, both solifenacin
doses were associated with signiﬁcant improvements
in the mean daily micturition frequency compared
with baseline; the micturition frequency was reduced
to about eight voids per day, and these results were
not inferior to those achieved with TOL4. The sec-
ondary efﬁcacy variable, mean micturition volume
per voiding, was also signiﬁcantly improved with all
three treatment groups, showing that the two solifen-
acin doses were not inferior to TOL4; indeed, the
increase was more signiﬁcant for the SOL10 group
than for the TOL4 group. The mean volume voided
per micturition has been used in randomised clinical
trials to assess the efﬁcacy of medical treatment. The
volume voided per micturition may be less affected
by placebo than the number of micturitions per day
and an increase in voided volume per micturition
indicates that the bladder capacity is greater at the
time of micturition (16). Therefore, signiﬁcant
increases in volume per micturition in the SOL10
group compared with the SOL5 and TOL4 groups
are meaningful. The magnitudes of changes in mean
daily urgency, urgency incontinence frequency and
nocturia demonstrated that solifenacin has a similar
efﬁcacy as tolterodine. The results of a European
double-blind tolterodine-controlled trial including
large numbers of randomised patients (1081 patients)
are quite different from our data (9). Compared with
tolterodine 2 mg twice daily, the changes in efﬁcacy
parameters such as episodes of urgency and urgency
incontinence were more marked in solofenacin 5 and
10 mg groups.
According to the present study, SOL5 is an appro-
priate initial therapy for OAB patients in Korea.
Although the changes in efﬁcacy variables are greater
with SOL10 than SOL5, these differences are not sta-
tistically signiﬁcant, with the exception of mean mic-
turition volume per voiding. In a prospective,
randomised, double-blind study in Japan comparing
placebo, SOL5, SOL10 and propiverine hydrochloride
20 mg, there were also no signiﬁcant differences in
the primary efﬁcacy variable, mean number of voids
per 24 h, between the SOL5 and SOL10 groups (17).
In the same study, among patients who had urgency
incontinence at baseline, 56.2% and 59.6% of
patients in the SOL5 and SOL10 groups, respectively,
achieved continence at study end-point. Likewise,
61.4%, 56.4% and 57.7% of incontinence patients
treated with SOL5, SOL10 and TOL4, respectively,
achieved continence at study end-point in the pres-
ent study (data not shown).
Antimuscarinic agents have unwanted effects on
other organs, the most common of which is dry
mouth, and these may interfere with patient compli-
ance and thus overall treatment efﬁcacy (5). Dry
mouth is common even with newer formulations
Figure 2 (A) Changes in the mean daily micturition frequency. (B) The mean micturition volume per voiding (ml). (C) The mean daily urgency
incontinence frequency. (D) The mean daily number of urgency episodes. (E) The mean number of nocturia episodes
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Thus, there is a need for more-tolerable therapeutic
options with proper symptom relief. Both doses of
solifenacin were well tolerated by patients, with only
a few discontinuations caused by AEs. Importantly,
the incidence of dry mouth was 7.6% in the SOL5
group and 19.5% in the SOL10 group, compared
with 18.6% in the TOL4 group. In the European
study, dry mouth was the most common AE but was
well tolerated and reported in 14.0%, 21.3% and
18.6% of patients in the SOL5, SOL10 and TOL4
groups, respectively (9). Although constipation and
blurred vision occurred more often in patients trea-
ted with solifenacin than in those treated with tolte-
rodine, most of these AEs were mild to moderate
and rarely led to discontinuation of therapy.
In isolated cell preparations from rats and mon-
keys, solifenacin showed signiﬁcantly more selectiv-
ity for the bladder over salivary gland tissue
compared with tolterodine (20). The results of the
present study are consistent with pharmacodynamic
observations in phase 1 studies that compared with
placebo, SOL5 has similar effects on salivary secre-
tion and on the visual near point (21). The clinical
effectiveness of SOL5 in terms of both tolerability
and efﬁcacy is clear from the present data, as it
was associated with the most-favourable therapeutic
index in the present study. These data are consis-
tent with preclinical data indicating the relative
selectivity of solifenacin for the bladder over the
salivary gland, particularly the low incidence of dry
mouth.
Table 3 Changes in the quality of life, as assessed by the King’s Health Questionnaire (ANOVA)
Quality of life Domain
Solifenacin succinate
5m gq d( N = 107) 10 mg qd (N = 111)
Tolterodine 2 mg bid (N = 111)
Adjusted mean change from baseline (N)
Adjusted mean change from baseline (N),
estimated difference to tolterodine, p-value
hierarchical test
General health perception )1.96 (110) )3.28 (107) )2.33 (111)
)1.32 )0.37
– 0.9827
Incontinence impact )12.10 (110) )13.60 (107) )15.94 (111)
)1.50 )3.84
– 0.2864
Role limitations )19.47 (107) )18.44 (105) )23.75 (111)
1.03 )4.28
– 0.4160
Physical limitations )20.39 (107) )20.97 (105) )25.26 (111)
)0.58 )4.87
– )0.2815
Social limitations )18.77 (103) )13.95 (105) )23.40 (110)
4.83 )4.62
– 0.5296
Personal relationships )7.78 (67) )9.31 (70) )7.08 (68)
)1.53 0.70
– 0.9792
Emotions )15.34 (105) )16.86 (107) )20.37 (110)
)1.52 )5.03
– 0.2369
Sleep⁄energy )13.66 (107) )15.68 (107) )18.75 (110)
)2.02 )5.09
– 0.1849
Severity measure )9.87 (99) )12.77 (105) )13.76 (106)
)2.90 )3.89
– 0.2420
Symptom severity )3.48 (110) )3.36 (107) )4.03 (111)
0.12 )0.55
– 0.4813
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the Kings Health Questionnaire scores from baseline,
demonstrating statistically signiﬁcant improvements
of patient quality of life. The mean change in Kings
Health Questionnaire scores from baseline was
greater in both the SOL5 and SOL10 groups com-
pared with the TOL4 group, although the difference
was not signiﬁcant. Kelleher et al. (22) reported qual-
ity of life data, assessed by the Kings Health Ques-
tionnaire from two phase 3, 12-week studies (1984
patients) and long-term extensions of these studies
(1637 patients) in which patients received solifenacin
for up to an additional 40 weeks. Pooled data from
the two studies showed that compared with placebo,
solifenacin was associated with signiﬁcant (p < 0.05)
improvements in nine of 10 quality of life domains.
About two-thirds of this overall improvement with
solifenacin occurred during the original 12-week
study, with an additional one-third reported during
the extension period.
Table 4 Incidence rates of adverse events after medication
Adverse events*
Solifenacin succinate
Tolterodine
2 mg bid
(N = 118), n (%)
5m gq d( N = 118),
n (%)
10 mg qd (N = 118),
n (%)
Gastrointestinal disorders 22 (18.64) 42 (35.59) 30 (25.42)
Dry mouth 9 (7.63) 23 (19.49) 22 (18.64)
Constipation 8 (6.78) 17 (14.41) 3 (2.54)
Dyspepsia 3 (2.54) 4 (3.39) 2 (1.69)
Abdominal pain upper 2 (1.69) 4 (3.39) 1 (0.85)
Eye disorders 17 (14.41) 25 (21.19) 18 (15.25)
Vision blurred 16 (13.56) 19 (16.10) 12 (10.17)
Dry eye NOS 0 (0.00) 1 (0.85) 3 (2.54)
Renal and urinary disorders 6 (5.08) 10 (8.47) 14 (11.86)
Difﬁculty in micturition 1 (0.85) 6 (5.08) 6 (5.08)
Urine ﬂow decreased 3 (2.54) 3 (2.54) 3 (2.54)
Vesical tenesmus 1 (0.85) 1 (0.85) 3 (2.54)
Infections and infestations 7 (5.93) 5 (4.24) 6 (5.08)
Cystitis NOS 3 (2.54) 2 (1.69) 2 (1.69)
Nasopharyngitis 1 (0.85) 1 (0.85) 3 (2.54)
Nervous system disorders 2 (1.69) 3 (2.54) 3 (2.54)
Injury, poisoning and procedural complications 0 (0.00) 5 (4.24) 2 (1.69)
General disorders and administration site conditions 0 (0.00) 1 (0.85) 4 (3.39)
Skin and subcutaneous tissue disorders 1 (0.85) 3 (2.54) 1 (0.85)
*Dictionary: MedDRA 5.0 (incidence of AEs ‡ 2.0%). NOS, not otherwise speciﬁed; AEs, adverse events.
Table 5 The mean changes in postvoid residual urine volume from baseline to end-point
Postvoid residual
volume (ml)
Solifenacin succinate
Tolterodine 2 mg bid (N = 118) 5m gq d( N = 118) 10 mg qd (N = 118)
Male Female Male Female Male Female
Baseline N 22 96 30 87 23 95
Mean (SD) 25.32 (31.18) 22.77 (33.45) 30.97 (28.90) 30.17 (37.89) 27.09 (28.30) 21.99 (36.50)
Range 0.00–99.00 0.00–195.00 0.00–97.00 0.00–173.00 0.00–90.00 0.00–247.00
End of study N 19 91 29 83 22 86
Mean (SD) 37.68 56.39) 29.93 (39.76) 41.97 (61.68) 35.14 (60.25) 34.04 (45.10) 26.78 (35.80)
Range 0.00–241.00 0.00–197.00 0.00–287.00 0.00–399.00 0.00–175.00 0.00–184.00
Change N 19 91 29 82 22 86
Mean (SD) 10.26 (48.59) 7.95 (39.26) 9.93 (54.32) 2.76 (49.31) 6.31 (39.55) 4.37 (29.42)
ANCOVA, treatment drug (p = 0.8257), gender (p = 0.2266).
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fenacin 5 and 10 mg compared with tolterodine ER
4 mg, all the OAB symptoms and quality of life
improved. The improvement rate was the greatest in
the SOL10 group, followed by the SOL5 and TOL4
groups although micturition volume per voiding
only had a statistical difference. The discontinuation
rates caused by AEs were low and were similar for
the three treatment arms. The dry mouth was the
lowest in the SOL5 group. Solifenacin 5 mg is a rec-
ommended starting dose in Korean patients with
OAB.
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